JP2014523404A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523404A5
JP2014523404A5 JP2014508540A JP2014508540A JP2014523404A5 JP 2014523404 A5 JP2014523404 A5 JP 2014523404A5 JP 2014508540 A JP2014508540 A JP 2014508540A JP 2014508540 A JP2014508540 A JP 2014508540A JP 2014523404 A5 JP2014523404 A5 JP 2014523404A5
Authority
JP
Japan
Prior art keywords
opioid receptor
drug
nalbuphine
dual
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014508540A
Other languages
English (en)
Japanese (ja)
Other versions
JP6134703B6 (ja
JP2014523404A (ja
JP6134703B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/035129 external-priority patent/WO2012149113A1/en
Publication of JP2014523404A publication Critical patent/JP2014523404A/ja
Publication of JP2014523404A5 publication Critical patent/JP2014523404A5/ja
Application granted granted Critical
Publication of JP6134703B2 publication Critical patent/JP6134703B2/ja
Publication of JP6134703B6 publication Critical patent/JP6134703B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014508540A 2011-04-29 2012-04-26 ジスキネジーの治療方法 Active JP6134703B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480415P 2011-04-29 2011-04-29
US61/480,415 2011-04-29
PCT/US2012/035129 WO2012149113A1 (en) 2011-04-29 2012-04-26 Method of treating dyskinesia

Publications (4)

Publication Number Publication Date
JP2014523404A JP2014523404A (ja) 2014-09-11
JP2014523404A5 true JP2014523404A5 (https=) 2015-07-30
JP6134703B2 JP6134703B2 (ja) 2017-05-24
JP6134703B6 JP6134703B6 (ja) 2017-08-02

Family

ID=

Similar Documents

Publication Publication Date Title
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2013527167A5 (https=)
MX2013001757A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
WO2007121913A3 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
JP2011068653A5 (https=)
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
MX2015011896A (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
JP2013542247A5 (https=)
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
WO2012054831A3 (en) Ready to use ketorolac formulations
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
JP2011137020A5 (https=)
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
NZ605469A (en) Nalbuphine-based formulations and uses thereof
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
NZ711179A (en) Oral formulations of deferasirox
HRP20201736T1 (hr) Postupak liječenja diskinezije
MY160652A (en) Pharmaceutical composition for oral administration
PH12014501408A1 (en) Immediate release multi unit pellet system
HK1203050A1 (en) Novel dosage and formulation
JP2008515801A5 (https=)
IL292725A (en) Benzazepines are combined for the treatment of Tourette syndrome
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
JP2014523404A5 (https=)